PMAs loom for pelvic organ prolapse mesh devices; J and J stops morcellator sales
This article was originally published in Clinica
The US FDA says that surgical meshes used for transvaginal repair of pelvic organ prolapse should be regulated under tougher standards based on health risks associated with the devices. The decision will affect companies including CR Bard, Covidien, Boston Scientific, Coloplast and Endo Pharmaceuticals (through its American Medical Systems unit). Johnson & Johnson was in the sector, but discontinued several of its vaginal meshes in 2012.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.